During the past decade, North York Diagnostic and Cardiac Centre conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 3 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 3 clinical trials were completed. i.e. 23.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "North York Diagnostic and Cardiac Centre" #1 sponsor was "Canadian Medical and Surgical Knowledge Translation Research Group" with 4 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "North York Diagnostic and Cardiac Centre" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "HLS Therapeutics, Inc" with 2 trials as a collaborator, "Unity Health Toronto" with 2 trials as a collaborator, "Western University, Canada" with 2 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "North York Diagnostic and Cardiac Centre" are "Heart Failure" (5 trials), "Cardiovascular Diseases" (4 trials), "Dyslipidemias" (2 trials), "Asymptomatic Carotid Artery Stenosis" (1 trials) and "Atherosclerotic Cardiovascular Disease" (1 trials). Many other conditions were trialed in "North York Diagnostic and Cardiac Centre" in a lesser frequency.

Most popular intervention types in "North York Diagnostic and Cardiac Centre" are "Drug" (13 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Empagliflozin" (3 trials), "Evolocumab" (2 trials), "Tirzepatide" (2 trials) and "Dulaglutide" (1 trials). Other intervention names were less common.

The vast majority of trials in "North York Diagnostic and Cardiac Centre" are 15 trials for "All" genders.

Currently, there are NaN active trials in "North York Diagnostic and Cardiac Centre". undefined are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in North York Diagnostic and Cardiac Centre, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in North York Diagnostic and Cardiac Centre, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".